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HIV research for preven-
tion has so far produced a 
mixed bag with no magic 
bullet, but results for an 
anti retroviral (ARV)-in-
fused vaginal ring that stays in place for 
30 days, potentially offering women up to 
50% (or more) protection against HIV and 
theoretically saving millions of lives over 
time, will be reported in 2016.
There are two parallel, almost identical 
major microbicide ring trials currently 
underway, the ASPIRE trial and the Ring 
trial. The results of the former are due 
in early 2016 – and if positive with high 
efficacy, the device will almost certainly be 
licensed for use. This potentially major leap 
forward in adherence to interventions for 
women, in addition to the HIV prevention 
armament of circumcision, male and 
female condoms, prevention of mother-
to-child transmission and oral ARVs 
(among others), is generating the most 
excitement among the South African (SA)-
led global community of HIV researchers, 
because of how far advanced its twinned 
international studies are. The research 
focus on female-initiated methods of HIV 
prevention makes solid sense on taking a 
quick glance at the statistics: of more than 
35.3 million people living with HIV, over 
half are women. In sub-Saharan Africa, 
where unprotected heterosexual sex is the 
primary HIV driver, women account for 
nearly 60% of adults with HIV. Young 
women are especially vulnerable, those 
aged 15 - 24 being twice as likely as young 
men to be infected with HIV. Efforts to 
promote abstinence, monogamy and the 
use of male condoms have either not done 
enough to stop the HIV epidemic or are 
not realistic in many settings. Women lack 
practical and discreet tools they can use 
to protect themselves from HIV infection. 
Many women are unable to negotiate 
successfully with their male partners to 
use condoms or to be faithful. Abstinence 
is simply not realistic for women who are 
married, who want children or who are at 
risk of violence.
ARV gel well ahead in 
the efficacy stakes
Findings of a confirmatory trial of the far 
earlier Durban-based CAPRISA 004 trial 
led by Prof. Salim Karim that showed an 
ARV-based microbicide gel to be 39% effec-
tive, which are being confirmed through 
the FACTS 001 trial by Prof. Helen Rees 
of the Wits Reproductive Health and HIV 
Institute and Prof. Glenda Gray, now 
Medical Research Council (MRC) CEO, 
will be released at the Conference on 
Retroviruses and Opportunistic Infections 
(CROI) in Seattle, USA, in late February 
next year. One of the major challenges with 
pre-exposure prophylaxis, including vaginal 
gel, is its low adherence threshold (the gel 
needs to be applied 12 hours before and 12 
hours after coitus). However, the CAPRISA 
004 trial is the only ‘proof of concept’ trial 
of a vaginal microbicide so far, and an 
improved efficacy result through the FACTS 
001 trial would increase options for those 
women who have a preference for gel as an 
HIV prevention method. The CAPRISA 004 
trial also showed efficacy of 50% protection 
against herpes simplex virus 2.
Other scientific advances are novel 
formulation of pre-exposure prophylaxis in 
the form of long-acting injectables. It is 
hoped that a decade from now we will 
have injectable ARVs offering prevention 
and treatment for HIV-negative and HIV-
positive people, respectively. The concept 
has gone through preclinical and animal 
studies and is currently being tested in early-
phase human trials. Based on safety and 
pharmacokinetic and pharmacodynamic 
data, the products are slated to move to 
phase 2/2b trials.
Vaccines to prevent HIV are much-needed 
options to add to the current toolbox 
of HIV prevention options. Prof. Gita 
Ramjee, Director of the HIV Prevention 
Research Unit at the MRC, speaking at the 
HIV Research for Prevention Conference 
in Cape Town (the first global conference 
to feature all forms of biomedical HIV 
intervention), said that the most exciting 
news on the vaccine front would be 
adapting the partially successful Thai 
HIV vaccine trial to a local HIV sub-type 
C virus. New local trials are planned, 
building on the moderate success of the 
Thai RV144 trial.
Adapted, longer-acting 
HIV vaccine would be a 
‘global game changer’
Gray told the conference that after 30 
years of trying to find a vaccine for 
HIV, scientists in Thailand announced 
this success in 2009. The vaccine 
offered people who received it almost 
60% protection from the virus, for the 
first year. After 3 years, recipients were 
31% less likely to contract the virus. 
Researchers in SA have managed to 
show two things so far: that it is safe to 
use on South Africans, and that it (i.e. 
the Thai clade) provokes an immune 
response. A new trial will start in January 
with the Thai vaccine modified to fight 
against the African strain of the virus, 
and strengthened to offer protection from 
HIV for a longer period than the Thai 
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Women lack practical and 
discreet tools they can use to 
protect themselves from HIV 
infection.
Nobody expects the vaccine 
to offer complete protection 
from the virus, but even 
30 - 40% protection will 
significantly reduce the rate of 
new infections. Gray said that 
should this kind of efficacy be 
shown, in 2019 researchers 
will apply for approval by the 
Medicines Control Council for 
use and sale. Should the local 
vaccine enhancement boost 
efficacy to 50%, the vaccine 
would be ‘a global game 
changer’.
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vaccine does. Participants will receive a 
booster vaccination after a year. No one 
expects the vaccine to offer complete 
protection from the virus, but even 30 - 
40% protection will significantly reduce 
the rate of new infections. Gray said that 
should this kind of efficacy be shown, in 
2019 researchers will apply for approval 
by the Medicines Control Council (MCC) 
for use and sale. Should the local vaccine 
enhancement boost efficacy to 50%, the 
vaccine would be ‘a global game changer’.
For now, all eyes on 
microbicide ring study 
results
Ramjee, an MRC veteran of two decades, 
said that her institution was the biggest 
contributor to the twinned microbicide 
ring studies, with six sites in Durban. 
Other sites include CAPRISA, Cape 
Town, Johannesburg, Malawi, Uganda and 
Zimbabwe. Underpinned by the Inter-
national Microbicides Partnership and 
the US National Institutes of Health-
funded Microbicide Trials Network, the 
‘sister studies’ involve 4 500 women and 
are being run concurrently to keep the 
timeline to potential approval and product 
access as short as possible. (Two efficacy 
trials are usually needed for a product to 
be considered for regulatory approval.) 
When the datasets are merged and the 
MCC takes a decision on the efficacy 
threshold (Ramjee speculates that the 
MCC will go for safety and efficacy, with 
an  upper bound of 60% and lower bound 
of 50%), the product can be licensed. 
‘We’ve completed enrolment with follow-
up by June next year. Then we begin the 
process of data cleaning, and we’re hoping 
for results by December 2015 or early 
in 2016.’ Asked how she felt, given that 
she’s been involved in all the large-scale 
microbicide trials so far, Ramjee said she 
was ‘a bit confident that this may show 
something, given that we are alleviating 
some of the daily adherence issues’. 
Emphasising that the other products 
may have been ‘perfectly good’, she said 
that adherence was historically the single 
biggest issue. Products for HIV prevention 
and treatment would only work if they 
were taken or used as required.
Ramjee said that another exciting product 
was a similar flexible ring that delivered 
both an ARV drug and a contraceptive drug 
for 3 months (currently in the early testing 
phase). This multipurpose technology is 
being developed to protect women from 
HIV and unintended pregnancies. The 
rings are being developed by various groups 
using ARV agents such as dapivirine and 
tenofovir. She said that given the high 
incidence of HIV among women in Africa, 
it was ‘imperative’ that women’s needs for 
HIV prevention were met. This included 
providing choices of various formulations 
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